Download Files:
Teglicar
$220 – $800
Products Details
Product Description
– Teglicar is a selective and reversible orally active liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1) inhibitor with an IC50 value of 0.68 μM and a Ki value of 0.36 μM. Teglicar has a potential antihyperglycemic propert. Teglicar can be used for the research of diabetes and neurodegenerative disease including Huntington’s disease (HD)[1][2].
Web ID
– HY-16482
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Metabolism-sugar/lipid metabolism
Molecular Formula
– C22H45N3O3
References
– [1]Roberto Conti, et al. Selective reversible inhibition of liver carnitine palmitoyl-transferase 1 by teglicar reduces gluconeogenesis and improves glucose homeostasis. Diabetes. 2011 Feb;60(2):644-51.|[2]Carla Bertapelle, et al. The Reversible Carnitine Palmitoyltransferase 1 Inhibitor (Teglicar) Ameliorates the Neurodegenerative Phenotype in a Drosophila Huntington’s Disease Model by Acting on the Expression of Carnitine-Related Genes. Molecules
CAS Number
– 250694-07-6
Molecular Weight
– 399.61
Compound Purity
– 98.0
SMILES
– O=C(N[C@H](CC([O-])=O)C[N+](C)(C)C)NCCCCCCCCCCCCCC
Clinical Information
– No Development Reported
Research Area
– Metabolic Disease; Neurological Disease
Solubility
– DMSO : 19 mg/mL (ultrasonic)|Ethanol : 100 mg/mL (ultrasonic;heat to 60°C)|H2O : 10 mg/mL (ultrasonic)
Target
– Endogenous Metabolite
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
